Table 3 Multivariable model of COM-B domain statements associated with the likelihood of stopping ADT overuse
Survey statements | TDF domain | COM-B domain(s) | Adjusted odds ratio (95% CI) | p-value |
|---|---|---|---|---|
I find patients are worried about the effect stopping ADT will have on their cancer | Beliefs about consequences | Motivation–Reflective (provider) Opportunity–Social (patient) | 0.22 (0.05–0.79) | 0.03 |
I want to give ADT recommendations consistent with those of my peers | Social influence | Opportunity–Social (provider) | 0.12 (0.01–0.67) | 0.04 |
I have concerns about side effects and castration resistance in patients with long-term use of ADT | Beliefs about consequences | Motivation–Reflective | 2.42 (0.60–9.95) | 0.21 |
I put a lot of weight on guideline recommendations regarding use of ADT as monotherapy (e.g., AUA or NCCN) | Environmental resources | Opportunity–Physical | 2.73 (0.50–15.90) | 0.24 |
I do not have adequate time for discussion about ADT | Environmental resources | Opportunity–Physical | 2.82 (0.31–65.40) | 0.41 |
I find talking about stopping ADT challenging | Skills–interpersonal | Capability–Psychological | 2.03 (0.35–14.30) | 0.44 |
I like to consider options other than ADT to manage patients with localized prostate cancer (e.g., definitive treatment, watchful waiting) | Knowledge | Capability–Psychological | 1.00 (0.01–100) | 0.99 |